Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.
Fiche publication
Date publication
octobre 2016
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HABERSETZER François, Dr MINELLO Anne
Tous les auteurs :
Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, Gagnieu MC, Grangé JD, Minello A, Guillaud O, Kamar N, Alric L, Leroy V
Lien Pubmed
Résumé
Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). Over the last few years, second-generation direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and sofosbuvir (SOF) is the backbone of most modern treatment strategies. Since SOF is eliminated through the kidney, the aim of this multicentre retrospective study was to assess its antiviral efficacy and safety in HCV-infected patients with severe renal failure [including haemodialysis (HD) patients].
Référence
Nephrol. Dial. Transplant.. 2016 Oct;: